BPTS:NSD-Biophytis SA (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.16

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

3.47K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

Biophytis SA (BPTS) Stock Analysis:
Based on the Biophytis SA stock forecasts from 0 analysts, the average analyst target price for Biophytis SA is not available over the next 12 months. Biophytis SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biophytis SA is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Biophytis SA’s stock price was USD 1.16. Biophytis SA’s stock price has changed by -22.67% over the past week, -43.41% over the past month and -90.00% over the last year.

About

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biolo ...Read More

Company Website : https://www.biophytis.com

Address : Sorbonne University, Paris, France, 75005

Employees : 26

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.42

52 Week High : 13.17

Short Ratio : 0.25

52 Week Low : 1.00

Shorted Shares : 6,341

200 Day Moving Average : 5.16

Shorted Shares Previous Month : 5,451

50 Day Moving Average : 2.06

Short Percentage : 0.02%

Shares Held by Institutions : 1.51%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

 USD72.19B 9.35 7.18
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD65.33B 26.96 18.70
MRNA Moderna Inc

N/A

 USD57.03B 4.22 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD38.17B 3.01 1.65
RPRX Royalty Pharma plc

N/A

 USD26.82B 29.06 15.54
SGEN Seagen Inc

N/A

 USD25.70B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

N/A

 USD19.45B 58.02 5.06
ARGX argenx SE

N/A

 USD17.61B N/A N/A

ETFs Containing BPTS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -78.28% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.28% 7% F 3% F
Trailing 12 Months  
Capital Gain -90.00% 8% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.00% 8% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -17.19% 22% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.19% 22% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 33.71% 83% B 47% F
Risk Adjusted Return -50.98% 20% F 12% F
Market Capitalization 0.02B 12% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.54 25% F 24% F
Price / Cash Flow Ratio -0.89 24% F 55% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -783.82% 3% F 2% F
Return on Invested Capital -146.43% 12% F 7% F
Return on Assets -52.81% 13% F 4% F
Debt to Equity Ratio 105.77% 18% F 21% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.25 94% A 90% A-
Short Percent 0.02% 100% A+ 97% A+
Beta 1.42 47% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector